NCT01442766

Donepezil Trial for Motor Recovery in Acute Stroke

A Randomised-controlled Trial of Donepezil for Motor Recovery in Acute Stroke

• Status: Withdrawn
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Imperial College London · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

AIMS: To establish: 1) whether motor deficits in acute stroke improve more in patients taking donepezil, relative to placebo, for 12 weeks; 2) whether brain functional MRI changes as a result of donepezil after 12 weeks.

Detailed description

Stroke is a major personal and social burden, being the commonest cause of severe adult disability. Recovery has been shown in animal models to be dependent upon adequate levels of acetylcholine within the brain - which in stroke is likely to be deficient. This is because acetylcholine-producing nerve cells in the brain are often damaged by strokes. Consequently, the investigators hypothesise that recovery may be improved by boosting acetylcholine levels in the brain - that can be readily achieved by treating with donepezil.

Conditions

• Acute Stroke

Interventions

Type	Name	Description
DRUG	Donepezil	5mg for 4 weeks, 10mg for 8 weeks if tolerated, or lower dose to continue
DRUG	Placebo	Inert pill that appears identical to donepezil pill. 1 pill for first 4 weeks, followed by 2 pills until end of study.

Timeline

• Start date: 2011-11-01
• Primary completion: 2013-11-01
• Completion: 2014-05-01
• First posted: 2011-09-29
• Last updated: 2024-04-12

Locations

1 site across 1 country: United Kingdom